nætur
Substances comparées par problème : dyspepsie, ballonnements, reflux, constipation, côlon irritable.
Ouvrir

Santé digestive

Guide scientifique complet des troubles gastro-intestinaux et solutions thérapeutiques validées

Les troubles digestifs affectent 40% de la population mondiale selon les critères Rome IV. Ce guide complet, basé sur les dernières méta-analyses et guidelines internationales, explore les mécanismes physiopathologiques et les interventions thérapeutiques validées pour optimiser votre santé gastro-intestinale.

25 minutes de lecture

Compléments alimentaires

02 / digestion
Naetur

02 / digestion

Découvrir
Voir tous les compléments →

Actualité

Quel temps de digestion avant le sport ?

Quel temps de digestion avant le sport ?

Optimiser la digestion avant le sport est un aspect essentiel avant une pratique physique. Une alimentation bien planifiée permet aux pratiq…

29 avr. 20264 min
Lire l’article
Soulager la digestion difficile avec des solutions naturelles

Soulager la digestion difficile avec des solutions naturelles

Vous souffrez de digestion difficile ou de problèmes de digestion ? Vous n’êtes pas seul. Selon un sondage IFOP de 2021 [1], près de la moit…

29 avr. 20267 min
Lire l’article
Le microbiote humain

Le microbiote humain

Le microbiote désigne l’ensemble complexe des microorganismes (bactéries, virus, champignons, archées) qui colonisent différentes zones du c…

29 avr. 202627 min
Lire l’article
Tous les articles →

Plantes recommandées

Curcuma

Curcuma

Voir la fiche
Cumin

Cumin

Voir la fiche
Anis vert

Anis vert

Voir la fiche
Gingembre

Gingembre

Voir la fiche
Cannelle

Cannelle

Voir la fiche
Mélisse

Mélisse

Voir la fiche
Toutes les plantes →

Praticiens spécialisés

AC

A Coeur De Soi

Naturopathe · Aix-en-Provence
Voir le profil
Af

A fleurs de peau

Naturopathe · Vergèze
Voir le profil
Al

A l'Aube de Soi

Naturopathe · Saint-Front
Voir le profil
Tous les praticiens →

Références scientifiques

  1. [1] Pittayanon R, et al. Gut microbiota in patients with irritable bowel syndrome: systematic review and meta-analysis. Gastroenterology. 2019;157(1):97-108. URL: https://pubmed.ncbi.nlm.nih.gov/30940523/
  2. [2] Sadeghi A, et al. Post-infectious Irritable Bowel Syndrome: A Narrative Review. Middle East J Dig Dis. 2019;11(2):69-75. URL: https://pubmed.ncbi.nlm.nih.gov/31380002/
  3. [3] Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci. 2011;12(8):453-466. URL: https://pubmed.ncbi.nlm.nih.gov/21750565/
  4. [4] Bonaz B, et al. The vagus nerve at the interface of the microbiota-gut-brain axis. Front Neurosci. 2018;12:49. URL: https://pubmed.ncbi.nlm.nih.gov/29467611/
  5. [5] Mawe GM, Hoffman JM. Serotonin signalling in the gut: functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013;10(8):473-86. URL: https://pubmed.ncbi.nlm.nih.gov/23797870/
  6. [6] Madison A, Kiecolt-Glaser JK. Stress, depression, diet, and the gut microbiota: human-bacteria interactions. Curr Opin Behav Sci. 2019;28:105-110. URL: https://pubmed.ncbi.nlm.nih.gov/32395568/
  7. [7] Magnus Y, et al. Bile Acid Diarrhea Is Associated With Increased Intestinal Permeability Compared With Irritable Bowel Syndrome-Diarrhea. Gastroenterology. 2022;162(4):1343-1345. URL: https://pubmed.ncbi.nlm.nih.gov/34922946/
  8. [8] Rinninella E, et al. Food Components and Dietary Habits: Keys for a Healthy Gut Microbiota Composition. Nutrients. 2019;11(10):2393. URL: https://pubmed.ncbi.nlm.nih.gov/31591348/
  9. [9] Jeffery IB, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61(7):997-1006. URL: https://pubmed.ncbi.nlm.nih.gov/22180058/
  10. [10] Vich Vila A, et al. Impact of commonly used drugs on the gut microbiome. Nat Commun. 2020;11(1):362. URL: https://pubmed.ncbi.nlm.nih.gov/31953381/
  11. [11] Parada Venegas D, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277. URL: https://pubmed.ncbi.nlm.nih.gov/30915065/
  12. [12] Chelakkot C, et al. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50(8):1-9. URL: https://pubmed.ncbi.nlm.nih.gov/30115904/
  13. [13] Fasano A. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Res. 2020;9:69. URL: https://pubmed.ncbi.nlm.nih.gov/32051759/
  14. [14] Menees SB, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110(3):444-454. URL: https://pubmed.ncbi.nlm.nih.gov/25732419/
  15. [15] Aguilera-Lizarraga J, et al. Immune activation in irritable bowel syndrome: what is the evidence? Nat Rev Immunol. 2022;22(11):674-686. URL: https://pubmed.ncbi.nlm.nih.gov/35296814/
  16. [16] Sperber AD, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114. URL: https://pubmed.ncbi.nlm.nih.gov/32294476/
  17. [17] Eusebi LH, et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms. Gut. 2018;67(3):430-440. URL: https://pubmed.ncbi.nlm.nih.gov/28232473/
  18. [18] Zhang X, et al. Meta-analysis of gut microbiota alterations in patients with irritable bowel syndrome. Front Microbiol. 2024;15:1492349. URL: https://pubmed.ncbi.nlm.nih.gov/39777150/
  19. [19] Rose M, et al. Analysis of the burden and economic impact of digestive diseases in the European Region. United European Gastroenterol J. 2022;10(7):716-754. URL: https://pubmed.ncbi.nlm.nih.gov/36093599/
  20. [20] Herekar AA, et al. Work Productivity and Activity Impairment in Irritable Bowel Syndrome: A Multifaceted Problem. Clin Exp Gastroenterol. 2018;11:237-248. URL: https://pubmed.ncbi.nlm.nih.gov/30254230/
  21. [21] Cassar GE, et al. Health-Related Quality of Life in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Gastroenterol Nurs. 2020;43(4):E102-E122. URL: https://pubmed.ncbi.nlm.nih.gov/32487960/
  22. [22] Goodoory VC, et al. The Socioeconomic Impact of Irritable Bowel Syndrome: An Analysis of Direct and Indirect Health Care Costs. Clin Gastroenterol Hepatol. 2023;21(9):2450-2458.e3. URL: https://pubmed.ncbi.nlm.nih.gov/36731587/
  23. [23] Black CJ, et al. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020;17(8):473-486. URL: https://pubmed.ncbi.nlm.nih.gov/32296140/
  24. [24] Velasco-Benítez CA, et al. Functional gastrointestinal disorders frequency by Rome IV criteria. An Pediatr (Engl Ed). 2022;97(1):38-46. URL: https://pubmed.ncbi.nlm.nih.gov/35534416/
  25. [25] Ghoshal UC, et al. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut Liver. 2017;11(2):196-208. URL: https://pubmed.ncbi.nlm.nih.gov/28274108/
  26. [26] Halmos EP, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67-75. URL: https://pubmed.ncbi.nlm.nih.gov/24076059/
  27. [27] Ford AC, et al. Systematic review with meta-analysis: the efficacy of probiotics, prebiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044-1060. URL: https://pubmed.ncbi.nlm.nih.gov/30294792/
  28. [28] Alammar N, et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical trials. BMC Complement Altern Med. 2019;19(1):21. URL: https://pubmed.ncbi.nlm.nih.gov/30654773/
  29. [29] Nirwan JS, et al. Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease: Systematic Review with Meta-analysis. Sci Rep. 2020;10(1):5814. URL: https://pubmed.ncbi.nlm.nih.gov/32242117/
  30. [30] Yadlapati R, et al. Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0. Neurogastroenterol Motil. 2021;33(1):e14058. URL: https://pubmed.ncbi.nlm.nih.gov/33373111/
  31. [31] Nirwan JS, et al. Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease: Systematic Review with Meta-analysis. Sci Rep. 2020;10(1):5814. URL: https://pubmed.ncbi.nlm.nih.gov/32242117/
  32. [32] Leiman DA, et al. Alginate therapy is effective treatment for gastroesophageal reflux disease symptoms: a systematic review and meta-analysis. Dis Esophagus. 2017;30(1):1-9. URL: https://pubmed.ncbi.nlm.nih.gov/27671545/
  33. [33] Pereira Rde S, et al. The potential therapeutic effect of melatonin in Gastro-Esophageal Reflux Disease. BMC Gastroenterol. 2010;10:7. URL: https://pubmed.ncbi.nlm.nih.gov/20082715/
  34. [34] Raveendra KR, et al. An Extract of Glycyrrhiza glabra (GutGard) Alleviates Symptoms of Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study. Evid Based Complement Alternat Med. 2012;2012:216970. URL: https://pubmed.ncbi.nlm.nih.gov/22829853/
  35. [35] Ford AC, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(10):1547-61. URL: https://pubmed.ncbi.nlm.nih.gov/25070051/
  36. [36] McFarland LV, et al. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16(18):2202-22. URL: https://pubmed.ncbi.nlm.nih.gov/20458757/
  37. [37] Blaabjerg S, et al. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients. Antibiotics (Basel). 2017;6(4):21. URL: https://pubmed.ncbi.nlm.nih.gov/29023420/
  38. [38] Dimidi E, et al. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014;100(4):1075-84. URL: https://pubmed.ncbi.nlm.nih.gov/25099542/
  39. [39] Hawrelak JA, et al. The causes of intestinal dysbiosis: a review. Altern Med Rev. 2004;9(2):180-97. URL: https://pubmed.ncbi.nlm.nih.gov/15253677/
  40. [40] Khanna R, et al. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014;48(6):505-12. URL: https://pubmed.ncbi.nlm.nih.gov/24100754/
  41. [41] Nikkhah Bodagh M, et al. Ginger in gastrointestinal disorders: A systematic review of clinical trials. Food Sci Nutr. 2019;7(1):96-108. URL: https://pubmed.ncbi.nlm.nih.gov/30680163/
  42. [42] Gibson PR, et al. Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. J Gastroenterol Hepatol. 2010;25(2):252-8. URL: https://pubmed.ncbi.nlm.nih.gov/20136989/
  43. [43] Chedid V, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014;3(3):16-24. URL: https://pubmed.ncbi.nlm.nih.gov/24891990/